- Merck & Co. Inc.
- Pfizer Inc.
- Boehringer Ingelheim International GmbH
- Novartis AG
- GlaxoSmithKline PLC
- Bayer AG
- AstraZeneca PLC
- Kaiser Permanente
- Bristol-Myers Squibb Co.
- Schering-Plough Corp.
- H. Lundbeck AS
- Eli Lilly & Co.
- MannKind Corp.
- Corus Pharma Inc.
- Pharmion Corp.
- Dov Pharmaceutical Inc.
- Nicox SA
- NitroMed Inc.
- Marina Biotech Inc.
- Gilead Sciences Inc.
- Alnylam Holding Co.
- Genentech Inc.
- Eyetech Inc.
- Amgen Inc.
- Biogen Inc.
- Genzyme Corp.
- Merck, Lundbeck terminate sleep drug license deal
- Merck will develop Dov depression candidates
- Merck & Co. evaluates NicOx's nitric oxide-donating compounds
- Merck, NitroMed develop NO-based products
- Merck, Nastech terminate obesity deal
- BMS and Gilead work on HIV combination drug
- Merck, Alnylam in RNAi-based technology agreement
- Merck, Alnylam end RNAi agreement for ophthalmic drugs
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.